頁籤選單縮合
題 名 | 精神分裂症藥物--Paliperidone Palmitate之剖析=Analysis of Schizophrenia Drug--Paliperidone Palmitate |
---|---|
作 者 | 古貞庭; | 書刊名 | 藥學雜誌 |
卷 期 | 28:2=111 2012.06[民101.06] |
頁 次 | 頁26-31 |
分類號 | 418.21 |
關鍵詞 | 精神分裂症; 新一代抗精神病藥物; 長效型針劑抗精神病藥物; 個人與社會功能; |
語 文 | 中文(Chinese) |
中文摘要 | 台灣精神分裂症患者約 10萬人,精神分裂症患者通常在確診後 2-5年內復發,一再復發會促使疾病惡化。因此,避免早期復發所進行的治療,對疾病的影響力可能更甚於病程較晚期的介入。病人在「無病識感症」 (anosognosia)的情況下,容易中斷用藥導致急性症狀復發,增加強迫住院治療的情況,使病人功能受到損傷,疾病持續惡化 。 新一代抗精神病藥物 (Second generation antipsychotic),能阻斷多巴胺第二型受體 D2 dopamine和血清素第二型 5-HT2A受體,除了對於精神分裂症症狀 (正向、負向、認知與情緒症狀 )皆有廣泛療效,且其副作用發生率較傳統抗精神病藥物低。 美國食品暨藥物管理局 (FDA)已於 2009年核可 paliperidone palmitate (Sustenna)用於精神分裂症的治療, paliperidone palmitate亦於 2011年4月通過國內主管機關 -衛生署的藥品許可證申請審核;提供一個月一次的新長效型抗精神病藥物,對於精神分裂症患者,及早使用長效型抗精神病藥物 (long-acting treatment),能避免早期復發、減少疾病惡化,改善患者的「個人與社會功能」 (PSP, personal and social performance),重建病人的未來。 |
英文摘要 | In Taiwan, about 10 million people with schizophrenia, patients with schizophrenia often relapse 2-5 years after diagnosis. This period is a critical period, and will lead to recurrence of disease worsening. Therefore, to avoid the early recurrence of disease progression will help break the cycle, carried out during this critical period of treatment, the influence of the disease may be even more late in the course of the intervention period. Knowledge of disease-free patients in the case of a sense of disorder, medication compliance is often poor, easy to interrupt drug use relapse of acute symptoms, increased force hospital treatment, the patients functional damage, disease continues to worsen. A new generation of antipsychotic drugs can block the D 2 dopamine and 5-HT2A receptor, in addition to the symptoms of schizophrenia (positive, negative, cognitive and emotional symptoms) have a wide effect, and the incidence of side effects than traditional antipsychotic drugs is low. U.S. Food and Drug Administration has approved Sustenna 2009 for the treatment of schizophrenia, Sustenna also in April 2011 by the competent national authority — the Department of Health's pharmaceutical license application process; this will benefit the domestic pharmaceutical schizophrenia patients, once a month to provide a new long-acting antipsychotics, for schizophrenia patients, early use of long-acting antipsychotics (long-acting treatment), to avoid early relapse, reduce disease progression and improve patient "Personal and social function" (PSP, personal and social performance), reconstruction of the patient's future. |
本系統中英文摘要資訊取自各篇刊載內容。